The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Decrease in the Number of People Living with HCV

Back to News Homepage

Next

Liver Care After Successful Hepatitis C Treatment

AbbVie’s HCV Drug Cocktail Cures 99% in Trial

March 5, 2014

Print this page

AbbVie Inc. is one step closer to marketing its two-drug combination for the treatment of Hepatitis C.

Bloomberg News

AbbVie Hepatitis C Combo Cures Almost All Patients in Late Trial

By Simeon Bennett March 03, 2014

AbbVie Inc. (ABBV:US)’s combination hepatitis C therapy cured almost all patients in a late-stage study, moving the company closer to marketing a treatment that will compete with Gilead Sciences Inc. (GILD:US) and Bristol-Myers Squibb Co. (BMY:US)

In a trial in 419 patients, AbbVie’s as-yet-unnamed drug cocktail cured 99 percent of those given it after 12 weeks, regardless of whether they added the older booster medicine ribavirin, the North Chicago-based company said today at the Conference on Retroviruses and Opportunistic Infections in Boston. AbbVie said it will seek U.S. approval this quarter.

Continue reading this entire article:
http://www.businessweek.com/news/2014-03-03/abbvie-hepatitis-c-combo-cures-almost-all-patients-in-late-trial

31 Comments
Share
Share

Previous

Decrease in the Number of People Living with HCV

Back to News Homepage

Next

Liver Care After Successful Hepatitis C Treatment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.